Mobile

Comparison of the long-term efficacy and safety of Lucentis versus Ozurdex in patients with visual impairment due to macular edema following retinal vein occlusion (central or branch vein) who have co...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005045-13

Comparison of the long-term efficacy and safety of Lucentis versus Ozurdex in patients with visual impairment due to macular edema following retinal vein occlusion (central or branch vein) who have completed the respective core study (CRFB002EDE17 or CRFB002EDE18)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate the ocular and non-ocular adverse events during the 6-months study period in patients treated with Lucentis (0.5 mg) vs. treated with Ozurdex

Critère d'inclusion

  • visual impairment due to macular edema following retinal vein occlusion (branch or central)

Liens